DC4U’s GlycoDCTM dendritic cell targeting technology could be applied to enhance traditional prophylactic vaccine efficacy. This could be achieved by using glycated modifications of the antigens used.
Our GlycoDCTM technology allows us to covalently couple any antigen of choice with stimulating glycans. Thus, any vaccine aimed to enhance long term protection by the induction of CD4+ and CD8+ cytotoxic responses can be considered. Although we currently do not have any project running, our technology is applicable for various infection disease that can be potentially cured by prophylactic vaccination strategies such as HIV-1 and Influenza virus infections. Therefore, we are looking for partners who are interested in co-development of the application for prophylactic vaccines.